Repeat Dosing Data for Capsulin Phase II in type 2 diabetes presented at the EASD Conference in Rome
Diabetology Limited, announced results from the 10-day repeat-dosing of Capsulin™ oral insulin in patients with type 2 diabetes at the European Association for the Study of Diabetes (EASD) meeting in Rome (Diabetology)
Oral GLP-1 Study Presented at the EASD Conference in Rome
Results from a preclinical study on Axcess™ oral formulated GLP-1 analogues have been presented in a poster presentation during the European Association for the Study of Diabetes (EASD) meeting in Rome (Diabetology)
New diabetes rate up 90 percent in past decade
The rate of new cases of diabetes soared by about 90 percent in the United States in the past decade, fueled by growing obesity and sedentary lifestyles (Reuters)
Effects of pioglitazone? on major cardiovascular adverse events in high risk patients with type 2 diabetes
The PROactive study failed to show a significant benefit for pioglitazone compared with placebo in people who had type 2 diabetes as well as other evidence of cardiovascular disease. Despite a re-analysis of secondary endpoint data from this study, claims of this showing a significant benefit for pioglitazone appear unjustified (National Prescribing Centre, UK)
GAD Treatment and Insulin Secretion in Recent-Onset Type 1 Diabetes
GAD-alum may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement ( NeJM )
Study Finds Preventative Diabetes Care Reduces Amputation Occurrence
The APMA study, conducted by an independent research firm, found that 25 percent of the 600 people surveyed who had suffered an amputation from diabetes said they should have seen a specialist – such as a podiatrist – sooner (Market Watch)
Drug may prevent diabetes in arthritis patients
The risk of developing diabetes is cut in half among rheumatoid arthritis patients who use hydroxychloroquine for treatment, according to research findings reported this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco (MedlinePlus)
Growing Number of Consumers Trust Online Resources Over Other Media for Researching Drug Treatment Information
60 percent would sign up for enewsletters – 25 percent would join email groups (PharmaLive)
Amylin says Byetta outperformed Januvia in trial
Eli Lilly and Co and Amylin Pharmaceuticals Inc said on Tuesday that a trial of their diabetes drug Byetta, which was recently linked with six deaths from pancreatitis, reduced glucose levels more than a rival drug from Merck & Co (BD Diabetes)
Tests show 2-year benefits of Merck diabetes drug
Merck & Co’s diabetes drug Januvia substantially improves blood sugar levels over two years of treatment when combined with the older drug metformin and is generally well tolerated, new data on Tuesday showed (BD Diabetes)
Phenomix and Forest Laboratories to Collaborate on Development and Commercialization of Dutogliptin in Diabetes
Laboratories, Inc. and Phenomix Corporation today announced that they have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus (PharmaLive)
Lilly Announces Launch of Color Differentiation System for Humalog and Humulin U-100 Insulin Products in the United States
With color differentiation, the redesigned labeling can help patients, health care providers and pharmacists accurately identify the insulin that has been prescribed (PharmaLive)
FDA Approves Sanofi-Aventis Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra® (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus (BioSpace)
Insulin Resistance and Obesity in Childhood
Several factors are implicated in the pathogenesis of obesity-related insulin resistance, such as increased free fatty acids and many hormones and cytokines released by adipose tissue (European Journal of Endocrinology)
The glycemic index of bread and biscuits is markedly reduced by the addition of a proprietary fiber
The fiber mix added to the flour used in the preparation of biscuits and bread markedly reduces their GI (NMCD)
Vitamin K Supplements Reduce Progression of Insulin Resistance in Older Men
Vitamin K supplementation for 36 months at doses attainable in the diet may reduce progression of insulin resistance in older men, according to the results of a randomized controlled trial (Medscape)
Inverse association reported between type 2 diabetes and high intake of certain foods
New study findings suggested that multiple food groups may collectively influence the risk for type 2 diabetes (Endocrine Today)
New Teaching Tools Foster Science and Diabetes Education in Native American Schools
The Diabetes Education in Tribal Schools’, “Health is Life in Balance”, K-12 curriculum will be launched by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, the Indian Health Service , the Centers for Disease Control and Prevention and eight tribal colleges and universities (NIH, USA)
Video Games Zap Kids’ Diabetes Risk
Nutrition Experts Creating Video Games to Help Children Prevent Obesity and Type 2 Diabetes (WebMD)
BT helps its 8,000 people with diabetes to tackle growing problem for businesses
BT today launched a campaign to try to help thousands of its people avoid developing Type 2 diabetes or manage it better if already diagnosed – by changing their lifestyle (BT, UK)
Systematic review: Cardiovascular outcomes in trials of oral diabetes medications
The authors note that clinical trials of oral therapies for type 2 diabetes mellitus have largely focused on intermediate clinical outcomes, such as changes in HbA1c, serum lipids and blood pressure. Specific effects CV risks remain unclear but such outcomes have ‘unequivocal clinical relevance’(National electronic Library for Medicines)
Beyond Glycemic Control: Managing Obesity and Cardiovascular Disease Risk for Patients With Type 2 Diabetes in the Primary Care Setting
With increasingly more individuals affected by diabetes, it is important for primary care clinicians to understand and effectively manage the comorbid conditions associated with this disease (PeerView inSight)
Expensive new diabetes drugs may not be worth the money
The annual cost of diabetes drugs in the USA have nearly doubled to $12.5 billion between 2001 and 2007, raising questions about whether this actually translates into improved care (PharmaTimes)
The Handbook for Vascular Risk Assessment, Risk Reduction and Risk Management
This handbook brings together in one place information on our current state of knowledge about vascular risk assessment, risk reduction and risk management. It has been designed to be comprehensive, giving an overview of the latest state of knowledge. 150-page PDF (National Screening Committee)
Annual Professional Conference 2009
Our flagship annual event for healthcare professionals working in the field of diabetes (Diabetes UK)
Glycemic Management of Type 2 Diabetes
How Tight Is Right and How to Get There (Archives of Internal Medicine)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications
Meta-analysis suggested that, compared with other oral diabetes agents and placebo, metformin was moderately protective and rosiglitazone possibly harmful, but lack of power prohibited firmer conclusions (Archives of Internal Medicine)
National Trends in Treatment of Type 2 Diabetes Mellitus, 1994-2007
Increasingly complex and costly diabetes treatments are being applied to an increasing population. The magnitude of these rapid changes raises concerns about whether these more costly therapies will result in proportionately improved outcomes (Archives of Internal Medicine)
Diabetes drug costs soaring, top $12B last year
Americans with diabetes nearly doubled their spending on drugs for the disease in just six years, with the bill last year climbing to an eye-popping $12.5 billion (Associated Press)
Researchers uniting to fight diabetes and heart disease
Health research and you – Diabetes. 2-page PDF (Research Australia)
Is a Priming Dose of Insulin Necessary in a Low-Dose Insulin Protocol for the Treatment of Diabetic Ketoacidosis?
A priming dose in low-dose insulin therapy in patients with DKA is unnecessary if an adequate dose of regular insulin of 0.14 unit · kg body weight–1 · h–1 (about 10 units/h in a 70-kg patient) is given (Diabetes Care)
Prandial Insulin and the Systemic Appearance of Meal-Derived Glucose in People With Type 1 Diabetes
Intriguingly, in this issue of Diabetes Care, Pennant et al. (2) report that the rate of meal-derived glucose appearance in people with type 1 diabetes is unchanged by administration of prandial insulin 20 min before meal ingestion (Diabetes Care)
Dietary Energy Density Predicts the Risk of Incident Type 2 Diabetes
This is the first large population-based prospective study to report that an energy-dense diet may be associated with increased risk of development of diabetes, independent of baseline obesity (Diabetes Care)
Pioglitazone-related insulin sensitivity boost mediates reduced NEFA levels
The authors suggest that “long-term administration of pioglitazone may promote reduced NEFA levels in part by increasing adipose tissue sensitivity to the anti-lipolytic effects of insulin (Medwire)
The sweeter side of ACE2: Physiological evidence for a role in diabetes
In this review we will examine the role of the renin-angiotensin system in the physiopathology and treatment of diabetes and highlight the potential benefits of the ACE2/Ang-(1-7)/Mas receptor axis, focusing on recent data about ACE2 (PubMed)
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance
Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research Trial (PubMed)
Canadian Diabetes Association Awards
A list of the 5 awards announced on 24th October (Canadian Diabetes Association)
The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia
Acomplia has been authorised in the EU since June 2006 as an adjunct to diet and exercise for the treatment of obese patients or overweight patients with associated risk factors (EMEA)
Sanofi’s Acomplia looks doomed after EU suspension
The CHMP said the new data from “post-marketing experience and ongoing clinical trials indicated that serious psychiatric disorders may be more common than in the clinical trials used in the initial assessment of the medicine”. (PharmaTimes)
Glycosmedia is also available as an App: